OM-85
Clinical data
Trade namesBroncho-Vaxom
Other namesOM 85BV
Identifiers
CAS Number

OM-85 or OM85 (trade name Broncho-Vaxom) is an immunostimulant. It is a combination of molecules extracted from the walls of bacteria that commonly cause respiratory infections.[1]

Uses

It has been sold, as Broncho-Vaxom, in Europe and some South American countries.[1] It is used for children with asthma or recurrent respiratory infections.[1]

Potential uses

It may help prevent Covid-19.[2]

It may prevent babies from developing asthma.[3][4]

Composition

It is a mix of lipopolysaccharides,[4] extracted from bacteria cell walls.

Clinical trials

It has been studied in numerous pediatric clinical trials.[2]

References

  1. 1 2 3 Sly P (11 June 2020). "M85: could bacteria in a capsule protect us from coronavirus and other respiratory infections?".
  2. 1 2 Cao C, Wang J, Li Y, Li Y, Ma L, Abdelrahim ME, Zhu Y (May 2021). "Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis". International Journal of Clinical Practice. 75 (5): e13981. doi:10.1111/ijcp.13981. PMC 7883224. PMID 33405321.
  3. ↑ Hart A (15 Feb 2022). "Aussie researchers make asthma breakthrough".
  4. 1 2 Troy NM, Strickland D, Serralha M, de Jong E, Jones AC, Read J, et al. (July 2022). "Protection against severe infant lower respiratory tract infections by immune training: Mechanistic studies". The Journal of Allergy and Clinical Immunology. 150 (1): 93–103. doi:10.1016/j.jaci.2022.01.001. hdl:10044/1/95014. PMID 35177255. S2CID 246844791.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.